找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Radiotherapy of Liver Cancer; Jinsil Seong Book 2021 Springer Nature Singapore Pte Ltd. 2021 radiation therapy for liver tumors.radiothera

[复制链接]
楼主: Agoraphobia
发表于 2025-3-28 17:01:56 | 显示全部楼层
Radiobiology of the Liveration-induced liver disease (RILD) remains a major limitation of RT. The pathophysiology, diagnosis, and treatment of RILD are discussed in this chapter. Classic RILD manifests with hepatomegaly, anicteric ascites, and thrombocytopenia, and alkaline phosphatase elevated out of proportion to other li
发表于 2025-3-28 21:31:41 | 显示全部楼层
发表于 2025-3-28 23:06:30 | 显示全部楼层
发表于 2025-3-29 06:31:01 | 显示全部楼层
Antiviral Therapy in Liver Cancerction, respectively. Antiviral therapy using nucleos(t)ide analogs (NA) reduces HCC occurrence and recurrence in HBV-related HCC. NA therapy also improves overall survival by preventing liver function deterioration and decompensation. Indefinite antiviral therapy is recommended for most patients wit
发表于 2025-3-29 09:53:58 | 显示全部楼层
发表于 2025-3-29 14:58:20 | 显示全部楼层
发表于 2025-3-29 18:54:08 | 显示全部楼层
Image-Guided Radiotherapydoses of RT safely while respecting the radiation dose limits of numerous normal tissues in the upper abdomen, including the liver itself. Challenges to the routine use of RT to treat hepatic malignancies include the low whole liver tolerance to RT and the proximity of liver tumors to other organs a
发表于 2025-3-29 21:39:17 | 显示全部楼层
Particle Beam Radiotherapyf HCC by particle therapy is expected to be 85–90% at 3 years and 80–90% at 5 years. Overall survival rate is expected to be 55–65% at 2 years and 20–50% at 5 years. The prognostic factors for survival considered are hepatic function and number and size of tumors..Adverse events due to particle ther
发表于 2025-3-30 00:19:45 | 显示全部楼层
发表于 2025-3-30 04:59:27 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-21 08:28
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表